Desferal: profile and news

New oral drug could make Thalassemia treatment less painful for ... Feb 8, 2006
...these problems, children with Thalassemia major needed regular treatment to remove the excess iron from their bodies for which Desferal (R) (deferoxamine ... - Daily Times,

To: National Desk Jan 9, 2006
Speaking about his study, Dr Pennell said that it "shows that deferiprone clears iron from the heart more effectively than desferal, and improves heart function ... - U.S. Newswire (press release),

FDA Approvals: Exjade, Oncaspar, Invanz Nov 17, 2005
As with deferoxamine injection (Desferal, made by Novartis), deferasirox was associated with a low incidence of ocular and auditory disturbances. ... - Medscape (subscription)

Novartis eyes market-beating cancer drug growth Nov 8, 2005
...blood, was priced at between $2,000 and $3,000 a month in the US market, around 20 percent more than the older and difficult to use drug, Desferal, which it ... - Reuters

Novartis Exjade Trial Failed To Show Non-Inferiority To Desferal ... Sep 28, 2005
Novartis' trial for oral iron chelating agent Exjade failed to show non-inferiority to the companyâ€™s marketed parenteral therapy Desferal, but may show ... - FDA Advisory Committee

Blood Advisory Committee Recommends Exjade by Novartis Oct 10, 2005
Exjade won unanimous committee support even though its trials did not demonstrate â€œnon-inferiorityâ€? to Desferal (deferoxamine), the only other drug ... - PharmExec.com,

UPDATE 2-US FDA panel backs Novartis blood disorder drug Sep 29, 2005
...developed Exjade, an oral tablet that dissolves in water and is taken once a day, as an alternative to its currently marketed treatment Desferal, which is ... - Reuters

UPDATE 1-US FDA staff say Novartis new iron drug no better Sep 28, 2005
Profile, Research) new Exjade drug to treat iron overload in blood transfusion patients,, did not appear to work as well as its current Desferal medicine, US ... - Reuters

US FDA staff say Novartis new iron drug no better Sep 28, 2005
Research) new drug to treat iron overload in blood transfusion patients, Exjade, did not appear to work as well as its current drug, Desferal, US regulatory ... - Reuters

FDA Panel recommends approval of Exjade for once-daily oral ... Oct 8, 2005
Desferal ( Deferoxamine ), which showed that Exjade significantly reduced liver iron concentration ( LIC ) at doses of 20-30 mg/kg/day. ... - Xagena.it,

FDA Advisory Committee Votes Unanimously to Recommend Approval of ... Sep 29, 2005
Desferal(R) (deferoxamine), which showed that Exjade significantly reduced liver iron concentration (LIC) at doses of 20-30 mg/kg/day. ... - Finanzen.net,

Cooley's Anemia Foundation Applauds Committee Decision on Exjade ... Sep 30, 2005
...method of removing that dangerous excess iron is through subcutaneous infusion of the iron chelator deferoxamine, commonly known by the brand name Desferal. ... - U.S. Newswire (press release),

Novartis says US FDA's BPAC committee unanimously recommends ... Sep 29, 2005
Exjade, which is to replace the group's current Desferal treatment, in June received priority review by the FDA as the first and only once-daily oral iron ... - Forbes

FDA View On Novartis Drug Exjade Unclear Sep 28, 2005
Exjade, if approved, would probably replace older Novartis drug Desferal, and could reach annual sales of $500M or more, analysts say. ... - New Ratings

SCDAA Responds Favorably to Positive Review of Exjade by FDA ... Sep 29, 2005
While patients have access to an infused iron chelation therapy, Desferal(R) (deferoxamine), many of them have been unable to comply with the treatment due to ... - PR Newswire (press release),

Novartis Shares Boosted By FDA Exjade View Sep 30, 2005
Sees sales of at least $10B by 2010. Says margins will be higher than those on Desferal, which Exjade will replace. Rates buy, CHF77 target. ... - New Ratings

Novartis Contributes 25 Infusion Pumps To RIPAS Sep 8, 2005
The pumps, which cost $1,000 each, will be distributed to thalassaemia patients who are in dire need of desferal (desferrioxamine) to remove the excess iron ... - Bru Direct,

Novartis Contributes 25 Infusion Pumps To RIPAS 08 Sep 2005
The pumps, which cost $1,000 each, will be distributed to thalassaemia patients who are in dire need of desferal (desferrioxamine) to remove the excess iron ... - Bru Direct,

Initiation Of New Study To Help Children With Sickle Cell Anaemia Sep 1, 2005
This ongoing treatment must later be combined with nightly injections of a drug (Desferal Â®) that eliminates excessive iron buildup caused by regular blood ... - MedIndia,

New treatment may help with sickle cell Sep 1, 2005
To prevent iron buildup, they must eventually receive nightly injections of Desferal, a drug that removes iron from their bodies. ... - United Press International

New ways to prevent stroke and reduce excess iron in sickle cell ... Sep 4, 2005
This ongoing treatment must later be combined with nightly injections of a drug ( Desferal Â® ) that eliminates excessive iron buildup caused by regular blood ... - I-Newswire.com (press release)

Novartis' Exjade Goes To Blood Products Committee Sept. 29 Aug 30, 2005
...iron chelatorâ€™s failure to meet the primary endpoint of non-inferiority to Novartisâ€™ currently marketed iron overload therapy Desferal (deferoxamine) in ... - FDA Advisory Committee

The other anemia Aug 2, 2005
Then, in the 1970s, an iron-removing treatment called Desferal came onto the market. Itâ€™s still the industry standard. â€œDesferal ... - Gilroy Dispatch (subscription)

Health Canada grants Priority Review for (PR)Exjade(TM) for ... Jul 14, 2005
The current standard of care in iron chelation is Desferal(*) (deferoxamine). ... (TM) Exjade is a trademark. (*) Desferal is a registered trademark. ... - Canada NewsWire (press release)

Urgent probe after needles for thalassaemics break Jul 23, 2005
...their treatment, thalassaemics undergo regular red blood cell transfusions and go through the difficult and painful infusion of a drug, Desferal several times ... - Cyprus Mail <**results**>

Novartis iron-treating drug could be launched by end 2005 Jun 22, 2005
Exjade,a tablet, provides similar benefits to patients as Desferal, another Novartis drug, which is today's standard therapy and requires lengthy infusions. ... - MarketWatch

Novartis Drug Exjade Could Be A Blockbuster Jun 21, 2005
Initially, Exjade is seen replacing Novartis' drug Desferal. The drugs help remove excess iron from the body. Exjade is much easier ... - New Ratings

The Drug Trial Jun 22, 2005
...disorder. As part of their treatment, they had to endure excruciatingly painful injections and infusions of a drug, Desferal. If ... - International Herald Tribune,